Current and Emerging Strategies for Treating Hepatic Encephalopathy

Critical Care Nursing Clinics of North America

Volumn 22, Issue 3, 2010, Pages 341-350

  Foster, Keith J ^a   Lin, Sonia ^a   Turck, Charles J ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Acarbose; Flumazenil; Hepatic encephalopathy; L carnitine; Lactulose; Probiotics

Indexed keywords

EID: 77955318495     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccell.2010.04.007     Document Type: Review

References (62)

1. Jalan R., Shawcross D., Davies N. The molecular pathogenesis of hepatic encephalopathy. Int J Biochem Cell Biol 2003, 35:1175-1181.
2. Butterworth R.F. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002, 4:221-227.
3. Munoz S.J. Hepatic encephalopathy. Med Clin North Am 2008, 92:795-812.
4. Sundaram V., Shaikh O.S. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009, 93:819-836.
5. Wright G., Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007, 21:95-100.
6. Ferenci P., Lockwood A., Mullen K., et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World congresses of Gastroenterology, Vienna. Hepatology 1998, 35:716-721.
7. Amodio P. Health related quality of life and minimal hepatic encephalopathy. It is time to insert 'quality' in health care. J Gastroenterol Hepatol 2009, 24:329-330.
8. Blendis L. Hepatic encephalopathy forward to the past. Gastroenterology 2006, 130:2239-2240.
9. Bajaj J.S. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008, 14:3609-3615.
10. Mostacci B., Ferlisi M., Baldi Antognini A., et al. Sleep disturbance and daytime sleepiness in patients with cirrhosis: a case control study. Neurol Sci 2008, 29:237-240.
11. Ahboucha S., Butterworth R.F. The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int 2008, 52:575-587.
12. Childers J.W., Arnold R.M. Hepatic encephalopathy in end-stage liver disease #188. J Palliat Med 2008, 11:1341-1342.
13. Olde Damink S.W.M., Jalan R., Dejong C.H.C. Interorgan ammonia trafficking in liver disease. Metab Brain Dis 2009, 24:169-181.
14. Riggio O., Efrati C., Catalona C., et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005, 42:1158-1164.
15. Deng D., Liao M.S., Qin J.P., et al. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. Hepatobiliary Pancreat Dis Int 2006, 5:232-236.
16. Braun M.M., Bar-Nathan N., Shaharabani E., et al. Postshunt hepatic encephalopathy in liver transplant recipients. Transplantation 2009, 87:734-739.
17. Albrecht J., Norenberg M.D. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006, 44:788-794.
18. Lavoie J., Giguère J.F., Pomier Layrargues G., et al. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem 1987, 49:692-697.
19. Gerber T., Schomerus H. Hepatic encephalopathy in liver cirrhosis. Pathogenesis, diagnosis and management. Drugs 2000, 60:1353-1370.
20. Wendon J., Lee W. Encephalopathy and cerebral edema in the setting of acute liver failure: pathogenesis and management. Neurocrit Care 2008, 9:97-102.
21. Jones E.A., Weissenborn K. Neurology and the liver. J Neurol Neurosurg Psychiatry 1997, 63:279-293.
22. Weissenborn K. Diagnosis of encephalopathy. Digestion 1998, 59(Suppl 2):22-24.
23. Lizardi-Cervera J., Almeda P., Guevara L., et al. Hepatic encephalopathy: a review. Ann Hepatol 2003, 2(3):122-130.
24. Ficker D.M., Westmoreland B.F., Sharbrough F.W. Epileptiform abnormalities in hepatic encephalopathy. J Clin Neurophysiol 1997, 14:230-234.
25. Eckstein A.K., Reichenbach A., Jacobi P., et al. Hepatic retinopathia. Changes in retinal function. Vision Res 1997, 37:1699-1706.
26. Mitchell S., Ayesh R., Barrett T., et al. Trimethylamine and foetor hepaticus. Scand J Gastroenterol 1999, 34:524-528.
27. Ortiz M., Jacas C., Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005, 42(Suppl 1):S45-S53.
28. Blei A.T., Cordoba J. Hepatic encephalopathy: practice guidelines. Am J Gastroenterol 2001, 96:1968-1976.
29. Avery G.S., Davies E.F., Brogden R.N. Lactulose: a review of its therapeutic and pharmacologic properties with particular reference to ammonia metabolism and its mode of action of portal systemic encephalopathy. Drugs 1972, 4(1):7-48.
30. Clausen M.R., Mortensen P.B. Lactulose, disaccharides and colonic flora. Clinical consequences. Drugs 1997, 53(6):930-942.
31. Patil D.H., Westaby D., Mahida Y.R., et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut 1987, 28:255-259.
32. Lactulose [package insert]. Lexi-drugs 2009, Lexi-drugs, Lexi-comp.
33. Kristalose® Prescribing Information 2006, Cumberland Pharmaceuticals, Nashville (TN).
34. Als-Nielsen B., Gluud L.L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 2004, 328:1046-1050.
35. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45(3):549-559.
36. Festi D., Vestito A., Mazzella, et al. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006, 73(Suppl 1):94-101.
37. Lawrence K.R., Klee J.A. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008, 28(8):1019-1032.
38. Neomycin. In: DRUGDEX® System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.
39. Neomycin [package insert] 2009, Lexi-drugs, Lexi-Comp.
40. Morgan M.H., Read A.E., Speller D.C.E. Treatment of hepatic encephalopathy with metronidazole. Gut 1982, 23:1-7.
41. Loft S., Sonne J., Døssing M., et al. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987, 22(1):117-123.
42. Uhl M.D., Riely C.A. Metronidazole in treating portosystemic encephalopathy. Ann Intern Med 1996, 124(4):455.
43. Adachi J., DuPont H.L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006, 42:541-547.
44. Xifaxan prescribing information 2008, Salix Pharmaceuticals.
45. Maclayton D.O., Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009, 43:77-84.
46. Bucci L., Palmieri C.G. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993, 13:109-118.
47. Massa R., Vallerino E., Dodero M. Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. Eur J Clin Res 1993, 4:4-18.
48. Pedretti G., Calzetti C., Missale G., et al. Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhosis: a double-blind, randomized trial. Ital J Gastroenterol 1991, 23:175-178.
49. Festi D., Mazzella G., Orsini M., et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res Clin Exp 1993, 54:598-609.
50. Alcorn J. Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. ACP J Club 2008, 149(5):11.
51. Huang E., Esrailian E., Spiegel B.M.R. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy-a decision analysis. Aliment Pharmacol Ther 2007, 26:1147-1161.
52. Sheth A.A., Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol 2008, 42(Suppl 2):S80-S84.
53. Malaguarnera M., Gargante M.P., Malaguarnera G., et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gasteroenterol Hepatol 2010, 22(2):199-206.
54. Sharma P., Sharma B.C., Puri V., et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008, 20:506-511.
55. Bajaj J.S., Saeian K., Christensen K.M., et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008, 103:1707-1715.
56. Loguercio C., Abbiati R., Rinaldi M., et al. Long-term effects of Enterococcus faecium SF68 alone versus lactulose in the treatment of patients with cirrhosis and grade 1 to 2 hepatic encephalopathy. J Hepatol 1995, 23:39-46.
57. Shores N.J., Keeffe E.B. Is oral l-acetyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Dig Dis Sci 2008, 53:2330-2333.
58. Malaguarnera M., Pistone G., Astuto M., et al. L-carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 2003, 21:271-275.
59. Gentile S., Guarine G., Romano M., et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005, 3(2):184-191.
60. Goulenok C., Bernard B., Cadranel J.F., et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2003, 16:361-372.
61. Barbaro G., Di Lorenzo G., Soldini M., et al. Flumazenil for hepatic encephalopathy Grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998, 28:374-378.
62. Flumazenil [package insert] 2007, Bedford Laboratories.